Advertisement

Basal and Exercise Plasma Levels of Atrial Natriuretic Peptide and Noradrenaline in Congestive Heart Failure

  • I. Tikkanen
  • H. Leinonen
  • H. Näveri
  • A. Sovijärvi
  • F. Fyhrquist
Conference paper

Abstract

Plasma levels of atrial natriuretic peptide (ANP) are elevated in patients with congestive heart failure (CHF) and related to the severity of the disease, judged by functional capacity of the patients [9] and by direct measurements of cardiac preload [8]. Thus, plasma ANP measurements have been suggested to be useful in the evaluation of the degree of cardiac impairment [4, 6, 8]. Plasma noradrenaline (NA) levels have also been shown to increase in proportion to the severity of CHF, and high NA levels are associated with increased mortality [1]. In the present study, plasma ANP and NA levels were measured at rest and during maximal exercise in patients with chronic CHF to see if there is a correlation between ANP, NA, and the severity of heart failure, assessed by maximal oxygen consumption ( \(\ddot V{O_2}\max \)).

Key words

Atrial natriuretic peptide ANP Noradrenaline Heart failure Exercise 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823PubMedCrossRefGoogle Scholar
  2. 2.
    Cohn JN, Ziesche S, Archibald DG (1986) Quantitative exercise tolerance test as a predictor of mortality in congestive heart failure: the V-HeFT study (Anstract). Circulation 74 [Suppl II]: 447Google Scholar
  3. 3.
    Franciosa J A (1984) Exercise testing in Short Communications chronic congestive heart failure. Am J Cardiol 53: 1447–1450PubMedCrossRefGoogle Scholar
  4. 4.
    Fyhrquist F, Tikkanen I, Totterman KJ, Hynynen M, Tikkanen T, Andersson S (1987) Plasma atrial natriuretic peptide in health and disease. Eur Heart J 8 [Suppl B]: 117–122PubMedGoogle Scholar
  5. 5.
    Leinonen H, Naveri H, Tikkanen I, Sovijarvi A, Fyhrquist F (1988) Basal and exercise plasma levels of atrial natriuretic factor in congestive heart failure. Am Heart J 116: 209–211PubMedCrossRefGoogle Scholar
  6. 6.
    Nishikimi T, Kohno M, Itagane H, Hirota K, Akioka K, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T (1988) Influence of exercise on plasma atrial natriuretic factor levels in patients with myocardial infarction. Am Heart J 115: 753–760PubMedCrossRefGoogle Scholar
  7. 7.
    Petzl DH, Hartter E, Osterode W, Bohm H, Woloszczuk W (1987) Atrial natriuretic peptide release due to physical exercise in healthy persons and in cardiac patients. Klin Wochenschr 65: 194–196PubMedCrossRefGoogle Scholar
  8. 8.
    Richards AM, Cleland JGF, Tonolo G, Mclntyre GD, Leckie BJ, Dargie HJ, Ball SG, Robertson JIS (1986) Plasma a natriuretic peptide in cardiac impairment. Br Med J 293: 409–412CrossRefGoogle Scholar
  9. 9.
    Tikkanen I, Fyhrquist F, Metsarinne K, Leidenius R (1985) Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 11: 66–69CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • I. Tikkanen
    • 1
    • 3
  • H. Leinonen
    • 2
  • H. Näveri
    • 2
  • A. Sovijärvi
    • 4
  • F. Fyhrquist
    • 1
    • 3
  1. 1.The Minerva Foundation Institute for Medical ResearchHelsinkiFinland
  2. 2.First Department of MedicineHelsinki University Central HospitalHelsinkiFinland
  3. 3.Fourth Department of MedicineHelsinki University Central HospitalHelsinkiFinland
  4. 4.Department of Pulmonary MedicineHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations